Research And Markets Research And Markets
0 CHECKOUT

Seizures - Pipeline Review, H2 2015

  • ID: 3455154
  • September 2015
  • 170 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Advicenne Pharma
  • Eisai Co., Ltd.
  • GW Pharmaceuticals Plc
  • H. Lundbeck A/S
  • INSYS Therapeutics, Inc.
  • Novartis AG
  • MORE

Seizures - Pipeline Review, H2 2015

Summary

The report ‘Seizures - Pipeline Review, H2 2015’, provides an overview of the Seizures’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Seizures, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Seizures and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updates following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Advicenne Pharma
  • Eisai Co., Ltd.
  • GW Pharmaceuticals Plc
  • H. Lundbeck A/S
  • INSYS Therapeutics, Inc.
  • Novartis AG
  • MORE

List of Tables

List of Figures

Introduction

REPORT COVERAGE

Seizures Overview

Therapeutics Development

Pipeline Products for Seizures - Overview

Pipeline Products for Seizures - Comparative Analysis

Seizures - Therapeutics under Development by Companies

Seizures - Therapeutics under Investigation by Universities/Institutes

Seizures - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Seizures - Products under Development by Companies

Seizures - Products under Investigation by Universities/Institutes

Seizures - Companies Involved in Therapeutics Development

Advicenne Pharma

Alexza Pharmaceuticals, Inc.

Catalyst Pharmaceutical Partners, Inc.

Eisai Co., Ltd.

GW Pharmaceuticals Plc

H. Lundbeck A/S

INSYS Therapeutics, Inc.

Ligand Pharmaceuticals, Inc.

Marathon Pharmaceuticals, LLC

Marinus Pharmaceuticals, Inc.

Novartis AG

OPKO Health, Inc.

Retrophin Inc.

Sage Therapeutics

SciFluor Life Sciences, LLC

SK Biopharmaceuticals Co., Ltd.

UCB S.A.

Ultragenyx Pharmaceutical Inc.

Upsher-Smith Laboratories, Inc.

Xenon Pharmaceuticals Inc.

Zogenix, Inc.

Seizures - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

ADD-405008 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ADV-6208 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ADV-6770 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

alprazolam - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AMPX-0079 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

AVL-5189 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

brivaracetam - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Cannabidiol - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CCG-63802 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CHEC-9 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

clobazam - Drug Profile

Product Description

Mechanism of Action

R&D Progress

cosyntropin - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CPP-115 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CUR-1916 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

diazepam - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Epidiolex - Drug Profile

Product Description

Mechanism of Action

R&D Progress

everolimus - Drug Profile

Product Description

Mechanism of Action

R&D Progress

fenfluramine hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

fosphenytoin sodium - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ganaxolone - Drug Profile

Product Description

Mechanism of Action

R&D Progress

lacosamide - Drug Profile

Product Description

Mechanism of Action

R&D Progress

levetiracetam - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MB-003 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

midazolam hydrochloride - Drug Profile

Product Description

Mechanism of Action

R&D Progress

MP-102 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NRP-2945 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Oligonucleotide for Dravet Syndrome - Drug Profile

Product Description

Mechanism of Action

R&D Progress

perampanel - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SAGE-217 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SAGE-689 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

selurampanel - Drug Profile

Product Description

Mechanism of Action

R&D Progress

sepranolone - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SF-0034 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecules to Inhibit Nav1.6 for Dravet Syndrome - Drug Profile

Product Description

Mechanism of Action

R&D Progress

TG-4155 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

UX-007 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

YKP-3089 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Seizures - Recent Pipeline Updates

Seizures - Dormant Projects

Seizures - Discontinued Products

Seizures - Product Development Milestones

Featured News & Press Releases

Sep 14, 2015: Eisai Announces FDA Acceptance of NDA for the Review of FYCOMPA (perampanel) Oral Suspension for Adjunctive Therapy in the Treatment of Partial-Onset Seizures and Primary Generalized Tonic-Clonic Seizures in Patients with Epilepsy Age 12 and Older

Sep 09, 2015: Marinus Pharmaceuticals Announces Positive End-of-Phase 2 Meeting With FDA for Ganaxolone in Focal Onset Seizures

Aug 24, 2015: FYCOMPA (perampanel) CIII Demonstrates a Significant Reduction in Primary Generalized Tonic-Clonic Seizure Frequency in Phase 3 Trial of Patients with Epilepsy Age 12 and Older

Aug 17, 2015: SAGE Announces First Patient Treated in Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus

Aug 06, 2015: SAGE Receives Special Protocol Assessment for Phase 3 STATUS Trial of SAGE-547 in Super-Refractory Status Epilepticus

Aug 04, 2015: Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol for the Treatment of Infantile Spasms

Jul 27, 2015: Eisai Submits New Drug Application In Japan For In-House-Discovered Antiepileptic Drug Perampanel As Adjunctive Therapy For Partial-Onset And Generalized Tonic-Clonic Seizures

Jul 08, 2015: First-in-Class Epilepsy Treatment Fycompa (Perampanel) Launches in the United Kingdom for Primary Generalised Tonic-Clonic Seizures

Jun 25, 2015: European Commission Approves Indication Expansion Of Eisai’s Antiepileptic Agent Fycompa For Adjunctive Treatment Of Primary Generalized Tonic-Clonic Seizures

Jun 22, 2015: U.S. FDA Approves Eisai’s Antiepileptic Agent Fycompa As Adjunctive Treatment For Primary Generalized Tonic-Clonic Seizures

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Seizures, H2 2015

Number of Products under Development for Seizures - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Number of Products under Investigation by Universities/Institutes, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Development, H2 2015

Products under Development by Companies, H2 2015

Products under Development by Companies, H2 2015 (Contd..1)

Products under Development by Companies, H2 2015 (Contd..2)

Products under Development by Companies, H2 2015 (Contd..3)

Products under Investigation by Universities/Institutes, H2 2015

Seizures - Pipeline by Advicenne Pharma, H2 2015

Seizures - Pipeline by Alexza Pharmaceuticals, Inc., H2 2015

Seizures - Pipeline by Catalyst Pharmaceutical Partners, Inc., H2 2015

Seizures - Pipeline by Eisai Co., Ltd., H2 2015

Seizures - Pipeline by GW Pharmaceuticals Plc, H2 2015

Seizures - Pipeline by H. Lundbeck A/S, H2 2015

Seizures - Pipeline by INSYS Therapeutics, Inc., H2 2015

Seizures - Pipeline by Ligand Pharmaceuticals, Inc., H2 2015

Seizures - Pipeline by Marathon Pharmaceuticals, LLC, H2 2015

Seizures - Pipeline by Marinus Pharmaceuticals, Inc., H2 2015

Seizures - Pipeline by Novartis AG, H2 2015

Seizures - Pipeline by OPKO Health, Inc., H2 2015

Seizures - Pipeline by Retrophin Inc., H2 2015

Seizures - Pipeline by Sage Therapeutics, H2 2015

Seizures - Pipeline by SciFluor Life Sciences, LLC, H2 2015

Seizures - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015

Seizures - Pipeline by UCB S.A., H2 2015

Seizures - Pipeline by Ultragenyx Pharmaceutical Inc., H2 2015

Seizures - Pipeline by Upsher-Smith Laboratories, Inc., H2 2015

Seizures - Pipeline by Xenon Pharmaceuticals Inc., H2 2015

Seizures - Pipeline by Zogenix, Inc., H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Stage and Target, H2 2015

Number of Products by Stage and Mechanism of Action, H2 2015

Number of Products by Stage and Route of Administration, H2 2015

Number of Products by Stage and Molecule Type, H2 2015

Seizures Therapeutics - Recent Pipeline Updates, H2 2015

Seizures - Dormant Projects, H2 2015

Seizures - Dormant Projects (Contd..1), H2 2015

Seizures - Discontinued Products, H2 2015

List of Figures

Number of Products under Development for Seizures, H2 2015

Number of Products under Development for Seizures - Comparative Analysis, H2 2015

Number of Products under Development by Companies, H2 2015

Comparative Analysis by Late Stage Development, H2 2015

Comparative Analysis by Clinical Stage Development, H2 2015

Comparative Analysis by Early Stage Products, H2 2015

Assessment by Monotherapy Products, H2 2015

Number of Products by Top 10 Targets, H2 2015

Number of Products by Stage and Top 10 Targets, H2 2015

Number of Products by Top 10 Mechanism of Actions, H2 2015

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015

Number of Products by Top 10 Routes of Administration, H2 2015

Number of Products by Stage and Top 10 Routes of Administration, H2 2015

Number of Products by Top 10 Molecule Types, H2 2015

Number of Products by Stage and Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Advicenne Pharma
Alexza Pharmaceuticals, Inc.
Catalyst Pharmaceutical Partners, Inc.
Eisai Co., Ltd.
GW Pharmaceuticals Plc
H. Lundbeck A/S
INSYS Therapeutics, Inc.
Ligand Pharmaceuticals, Inc.
Marathon Pharmaceuticals, LLC
Marinus Pharmaceuticals, Inc.
Novartis AG
OPKO Health, Inc.
Retrophin Inc.
Sage Therapeutics
SciFluor Life Sciences, LLC
SK Biopharmaceuticals Co., Ltd.
UCB S.A.
Ultragenyx Pharmaceutical Inc.
Upsher-Smith Laboratories, Inc.
Xenon Pharmaceuticals Inc.
Zogenix, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

RELATED PRODUCTS from Db